secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2024-08-29T23:59:59+00:00
Accession:  0001651308-24-000110
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene reports H1 2024 R&D expenses by product; total R&D up 10% YoY to $915M
------------------------------------------------------------------------------

- Zanubrutinib R&D expense $62.9M in H1 2024, down 22% from $81.1M in H1 2023.
- Tislelizumab R&D expense $34.5M in H1 2024, down 27% from $47.0M in H1 2023.
- Bcl-2 (BGB-11417) R&D expense $38.6M in H1 2024, up 120% from $17.5M in H1 2023.
- Total R&D expense $915.1M in H1 2024 vs $831.3M in H1 2023, +10.1% YoY.
- R&D collaboration projects $82.5M in H1 2024, up from $23.3M in H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130824000110/0001651308-24-000110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130824000110/bgne-20240829.htm
  HTML page:      https://secwatch.observer/filing/0001651308-24-000110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer